The Amgen Pharmaceutical Company Joins the CATALIS Network
CATALIS is pleased to welcome the Amgen pharmaceutical company to its Network of Partners. This biotechnology industry pioneer is dedicated to developing new treatments for various conditions, including rare diseases.
Amgen joins the many industry partners who are involved in the Network: Abbvie, Alexion, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences Canada Inc., GSK, Lilly Canada, Merck, Novartis, Novo Nordisk Canada Inc., Pfizer, Roche, Sanofi, Takeda, and Vertex.
These pharmaceutical partners support CATALIS in its mission to optimize clinical research in Quebec to accelerate the development of innovative care for the benefit of the province’s patients.
“Amgen is committed to developing new therapies to treat serious illnesses — a long and careful process. One of the most important steps in this process is conducting clinical trials. We are very excited to partner with CATALIS and join their Network with the goal of bringing innovative therapies to patients more quickly. We recognize the world-class quality of the clinician-researchers and the institutions in Quebec, and we are particularly looking forward to the FAST TRACK Evaluation Service to conduct clinical trials in Quebec which will accelerate the execution of our trials, for the benefit of patients.” – Ugur Gunaydin, Vice President and General Manager, Amgen Canada
